Target intelligence / Profile preview

Histone H3 pseudogene 15 (H3P15)

Target: H3P15
Molecular classification: Pseudogene, Other (Histone)

Overview

H3 histone pseudogene 15 (H3P15), also named histone cluster 3 H3 pseudogene, is classified as a pseudogene of the histone H3 family in humans. Unlike functional histone H3 genes, which encode core histone proteins critical for nucleosome structure and epigenetic regulation, H3P15 lacks evidence of encoding a functional protein product and is annotated as a non-functional genomic element. Pseudogenes such as H3P15 may arise from duplication or retrotransposition events but do not contribute to core histone pools involved in chromatin architecture, cell cycle regulation, or disease processes[1][3][5]. Current evidence does not support a role for H3P15 as a protein-coding gene, biomarker, or therapeutic target.

Other names: histone cluster 3 H3 pseudogene, H3P15H3 histone pseudogene 15

Beyond the preview

Go deeper on Histone H3 pseudogene 15 (H3P15).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone H3 pseudogene 15 (H3P15).

Explore the full profile